Athena Athena

X

Find the latest Drugs in Development and Pipeline Prospector News of InflaRx.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
InflaRx
Germany Flag
Country
Country
Germany
Address
Address
InflaRx N.V. Winzerlaer Str. 2 07745 Jena
Telephone
Telephone
+49 (0)3641 508 180
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

INF904 is an orally administered low molecular weight C5aR inhibitor which is under phase 1 clinical development for the treatment of inflammatory diseases.


Lead Product(s): INF904

Therapeutic Area: Immunology Product Name: INF904

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 04, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Gohibic (vilobelimab) is a first-in-class monoclonal anti-human complement factor C5a antibody, which demonstrates high selectivity towards its target in human blood, investigated for the treatment of Pyoderma Gangrenosum.


Lead Product(s): Ifx-1

Therapeutic Area: Dermatology Product Name: Gohibic

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 06, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

INF904 is an orally administered small molecule inhibitor of C5a-induced signaling via the receptor C5aR, which is investigated for the treatment of inflammatory diseases.


Lead Product(s): INF904

Therapeutic Area: Immunology Product Name: INF904

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 11, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Gohibic (vilobelimab) is a first-in-class monoclonal anti-human complement factor C5a antibody, which demonstrates high selectivity towards its target in human blood, used for the treatment of Critically Ill COVID-19 Patients.


Lead Product(s): Ifx-1

Therapeutic Area: Infections and Infectious Diseases Product Name: Gohibic

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 30, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Gohibic (vilobelimab) is a first-in-class monoclonal anti-human complement factor C5a antibody that has been granted an approval for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation.


Lead Product(s): Ifx-1

Therapeutic Area: Infections and Infectious Diseases Product Name: Gohibic

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 21, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the terms of the agreement, WuXi Biologics will provide cGMP manufacturing of Gohibic (vilobelimab), a first-in-class monoclonal anti-human complement factor C5a antibody for the treatment of COVID-19.


Lead Product(s): Ifx-1

Therapeutic Area: Infections and Infectious Diseases Product Name: Gohibic

Highest Development Status: ApprovedProduct Type: Large molecule

Recipient: WuXi Biologics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership May 16, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The Company intends to use the net proceeds from the offering to fund the continued development of IFX-1 (vilobelimab), a chimeric monoclonal IgG4 antibody that specifically binds with high affinity to the soluble form of human C5a.


Lead Product(s): Ifx-1

Therapeutic Area: Infections and Infectious Diseases Product Name: IFX-1

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Raymond James & Associates

Deal Size: $46.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering April 18, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The Company intends to use the net proceeds from the offering to fund the continued development of IFX-1 (vilobelimab),a chimeric monoclonal IgG4 antibody that specifically binds with high affinity to the soluble form of human C5a.


Lead Product(s): Ifx-1

Therapeutic Area: Infections and Infectious Diseases Product Name: IFX-1

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Raymond James & Associates

Deal Size: $40.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering April 14, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The Company intends to use the net proceeds from the offering to fund the continued development of IFX-1 (vilobelimab), an anti-C5a monoclonal antibody, in patients with severe COVID-19.


Lead Product(s): Ifx-1

Therapeutic Area: Infections and Infectious Diseases Product Name: IFX-1

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Raymond James & Associates

Deal Size: $40.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering April 11, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Gohibic (vilobelimab) is a first-in-class monoclonal anti-human complement factor C5a antibody that has been granted an EUA for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation.


Lead Product(s): Ifx-1

Therapeutic Area: Infections and Infectious Diseases Product Name: Gohibic

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 04, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY